Auspex Pharmaceuticals 10-Q 7 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 01, 2014
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'ASPX	'
Entity Registrant Name	'Auspex Pharmaceuticals, Inc.	'
Entity Central Index Key	'0001454189	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Non-accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	27,341,980

CONDENSED_BALANCE_SHEETS

CONDENSED BALANCE SHEETS (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$14,641	$36,650
Marketable securities	97,064	'
Prepaid expenses and other current assets	1,192	242
Total current assets	112,897	36,892
Deferred offering costs	349	1,817
Property and equipment, net	136	26
Other assets	139	137
Total assets	113,521	38,872
Current liabilities:	'	'
Accounts payable	2,498	1,365
Accrued liabilities	3,952	2,127
Total current liabilities	6,450	3,492
Long-term debt, less discount of $495 and $580, respectively	14,505	14,420
Preferred stock warrant liability	'	3,975
Other long-term liabilities	194	77
Total liabilities	21,149	21,964
Commitments and contingencies (Note 9)	'	'
Convertible preferred stock, par value $0.0001; 10,000,000 and 68,694,006 shares authorized at June 30, 2014 and December 31, 2013, respectively; none and 64,790,302 shares issued and outstanding at June 30, 2014 and December 31, 2013, respectively; $0 and $91,726 liquidation preference at June 30, 2014 and December 31, 2013, respectively	'	81,846
Stockholders’ equity (deficit):	'	'
Common stock, par value $0.0001; 200,000,000 and 86,500,000 shares authorized at June 30, 2014 and December 31, 2013, respectively; 23,719,480 and 1,128,702 issued and 22,940,412 and 173,147 outstanding, excluding 779,068 and 955,555 shares subject to repurchase at June 30, 2014 and December 31, 2013, respectively	2	'
Additional paid-in capital	178,331	542
Accumulated deficit	-85,988	-65,480
Accumulated other comprehensive income	27	'
Total stockholders’ equity (deficit)	92,372	-64,938
Total liabilities, convertible preferred stock and stockholders’ equity (deficit)	$113,521	$38,872

CONDENSED_BALANCE_SHEETS_Paren

CONDENSED BALANCE SHEETS (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Debt Instrument, Unamortized Discount	$495	$580
Convertible Preferred stock, par value	$0.00	$0.00
Convertible Preferred stock, shares authorized	10,000,000	68,694,006
Convertible Preferred stock, shares issued	0	64,790,302
Convertible Preferred stock, shares outstanding	0	64,790,302
Convertible Preferred stock, liquidation preference	$0	$91,726
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	200,000,000	86,500,000
Common stock, shares issued	23,719,480	1,128,702
Common stock, shares outstanding	22,940,412	173,147
Common stock, shares subject repurchase	779,068	955,555

CONDENSED_STATEMENTS_OF_OPERAT

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Operating expenses:	'	'	'	'
Research and development	$7,131	$2,432	$10,563	$4,163
General and administrative	2,908	385	5,582	1,284
Total operating expenses	10,039	2,817	16,145	5,447
Operating loss	-10,039	-2,817	-16,145	-5,447
Other income (expense)	'	'	'	'
Interest income and other expense, net	-346	-29	-729	-53
Other financing expense	'	-147	'	-184
Change in fair value of preferred stock warrant liability	'	104	-3,634	490
Total other (expense) income	-346	-72	-4,363	253
Net loss	-10,385	-2,889	-20,508	-5,194
Unrealized gain on available-for-sale securities, net	49	'	27	'
Other comprehensive gain	49	'	27	'
Comprehensive loss	($10,336)	($2,889)	($20,481)	($5,194)
Net loss per share, basic and diluted	($0.45)	($21,886)	($1.15)	($39,348)
Weighted-average common shares outstanding, basic and diluted	22,853,896	132	17,818,476	132

CONDENSED_STATEMENTS_OF_CASH_F

CONDENSED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Operating activities	'	'
Net loss	($20,508)	($5,194)
Reconciliation of net loss to net cash used in operating activities:	'	'
Depreciation	18	8
Change in fair value of preferred stock warrant liability	3,634	-490
Amortization of debt discount on notes payable	85	'
Amortization of premium on investment	287	'
Other financing expense	'	184
Stock-based compensation	1,411	78
Change in operating assets and liabilities:	'	'
Prepaid expenses and other current assets	-950	-30
Other assets	1,513	4
Accounts payable and accrued expenses	3,085	434
Net cash used in operating activities	-11,425	-5,006
Investing activities	'	'
Purchases of marketable securities	-102,824	'
Maturities of marketable securities	5,500	'
Purchases of property and equipment	-128	-5
Net cash used in investing activities	-97,452	-5
Financing activities	'	'
Proceeds from the issuance of convertible preferred stock, net of issuance costs	'	1,964
Proceeds from exercise of warrants and stock options and stock issuances under employee stock purchase plan	264	'
Proceeds from the issuance of common stock, net of fees	86,604	'
Net cash provided by financing activities	86,868	1,964
Decrease in cash and cash equivalents	-22,009	-3,047
Cash and cash equivalents at beginning of period	36,650	4,279
Cash and cash equivalents at end of period	14,641	1,232
Supplemental disclosure of cash flow information	'	'
Cash paid for interest expense	$562	'

Organization

Organization	6 Months Ended
	Jun. 30, 2014
Organization	'
	1. Organization
	Auspex Pharmaceuticals, Inc. (the “Company”) was founded on February 28, 2001 (“inception”), incorporated in California upon inception and subsequently reincorporated in Delaware in June 2007. The Company is a biopharmaceutical company focused on the development and commercialization of novel medicines for the treatment of orphan diseases. The Company’s pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea associated with Huntington’s disease, tardive dyskinesia and Tourette syndrome, as well as other orphan indications.
	From inception through June 30, 2014, the Company has devoted substantially all of its efforts to research, product development, raising capital, and building corporate infrastructure and has not generated any revenues from its planned principal operations. The Company has a limited operating history and the sales and income potential of the Company’s business and market are unproven. The Company has experienced net losses and negative cash flows from operating activities since its inception, and, as of June 30, 2014, had an accumulated deficit of $86.0 million.
	The Company expects to continue to incur net losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company’s cost structure. The Company plans to continue to fund its losses from operations and capital funding needs through future debt and equity financing or through collaborations or partnerships with other companies. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company’s business, results of operations and future prospects.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Summary of Significant Accounting Policies	'
	2. Summary of Significant Accounting Policies
	Basis of Presentation
	The Company’s financial statements are prepared in accordance with U.S. generally accepted accounting principles and with the rules and regulations of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements. These unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, consisting of only normal recurring accruals, which in the opinion of management are necessary to present fairly the Company’s financial position as of the interim date and results of operations for the interim periods presented. The preparation of the Company’s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to the valuation of convertible preferred stock warrants, equity awards and clinical trial accruals. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.
	Interim results are not necessarily indicative of results for a full year or future periods, and these condensed financial statements should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2013, included in its Annual Report on Form 10-K filed with the SEC on March 28, 2014.
	Segment Reporting
	Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment.
	Reverse Stock Split
	On January 16, 2014, the Company effected a 1-for-4.5 reverse stock split of the Company’s issued and outstanding shares of common stock. All issued and outstanding common stock and per share amounts contained in the Company’s financial statements have been retroactively adjusted to reflect the January 2014 reverse stock split for all periods presented.
	Cash, Cash Equivalents and Marketable Securities
	Cash and cash equivalents consist of cash and highly liquid securities with maturities at the date of acquisition of ninety days or less. Investments with maturities at the date of acquisition of more than ninety days are considered marketable securities and have been classified by management as available-for-sale. Such investments are carried at fair value, with unrealized gains and losses included as a separate component of stockholders’ equity. Realized gains and losses from the sale of available-for-sale securities or the amounts, net of tax, reclassified out of accumulated other comprehensive income, if any, are determined on a specific identification basis.
	Fair Value of Financial Instruments
	The Company measures certain financial assets and liabilities at fair value based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants.
	Convertible Preferred Stock Warrants
	The Company accounts for its warrants and other derivative financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument. Warrants classified as derivative liabilities are recorded on the Company’s balance sheet at their fair value on the date of issuance and are revalued at each subsequent balance sheet date, with fair value changes recognized as increases or reductions to other income (expense) in the statements of operations. The Company’s convertible preferred stock warrants were classified as liabilities, and the Company estimated the fair value of these liabilities using option pricing models and assumptions that were based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for expected volatility, expected life, yield, and risk-free interest rate. In connection with the completion of the Company’s initial public offering (“IPO”) in February 2014, all the outstanding warrants to purchase shares of preferred stock automatically converted into warrants to purchase shares of common stock. As a result of the IPO and warrant conversion, the Company reclassified the warrant liability as stockholders’ equity because the converted warrants met the definition of an equity instrument under derivative accounting guidance.  The Company performed the final remeasurement of the warrant liability as of the IPO date in February 2014, and recorded the $3.6 million change in fair value as other income (expense) at that time.
	Stock-Based Compensation Expense
	Stock options issued pursuant to the Company’s 2014 Equity Incentive Plan (the “2014 Plan”) and 2010 Equity Incentive Plan (the “2010 Plan”) and shares subject to purchase through the Company’s 2014 Employee Stock Purchase Plan (the “ESPP”) are valued using the Black-Scholes option pricing model on the date of grant or subscription period. This option pricing model involves a number of estimates, including the expected term of an award or subscription period, the anticipated stock volatility and risk-free interest rates. Stock-based compensation expense is recognized using the straight-line method and is based on the value of the portion of stock awards that are ultimately expected to vest or the number of shares estimated to be issued pursuant to ESPP.
	The table below summarizes the total stock-based compensation expense included in the Company’s statements of operations for stock options and shares subject to purchase under the ESPP for the periods presented (in thousands):
		Three Months Ended June 30,				Six Months Ended June 30,
		2014		2013		2014		2013
	Research and development	$	466	$	20	$	595	$	37
	General and administrative		441		1		816		41
	Total stock-based compensation expense	$	907	$	21	$	1,411	$	78
	Net Loss per Share
	Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, convertible preferred stock, unvested restricted common stock subject to repurchase, stock options and convertible preferred stock warrants are considered to be potentially dilutive securities but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. Therefore, basic and diluted net loss per share were the same for all periods presented.
	The following table sets forth the total number of outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive:
		June 30,
		2014		2013
	Convertible preferred stock		-		9,625,465
	Warrants to purchase convertible preferred stock		-		863,613
	Warrants to purchase common stock		708,207		-
	Common stock options		2,009,646		552,116
	Common stock subject to repurchase		799,068		-
			3,516,921		11,041,194
	Recent Accounting Pronouncements
	In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminates the financial reporting distinction between development stage entities and other reporting entities, thereby eliminating the requirements to present inception-to-date information in the statements of operations and stockholders’ equity and cash flow, or label the financial statements as those of a development stage entity. The Company has elected to early adopt this guidance, as permitted, for its financial statements for the year ended December 31, 2014, including this quarterly report, and therefore has no longer labeled its financial statements as those of a development stage entity or included any inception-to-date information.

Fair_Value_Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2014
Fair Value Measurements	'
	3. Fair Value Measurements
	The Company follows authoritative accounting guidance, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.
	As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:
	Level 1:	Observable inputs such as quoted prices in active markets;
	Level 2:	Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
	Level 3:	Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
	The carrying amounts of the Company’s prepaid expenses, other current assets, accounts payable and accrued liabilities are generally considered to be representative of their fair value because of the short nature of these instruments. Further, based upon borrowing rates currently available to the Company for loans with similar terms, the Company believes the fair value of its note payable approximates its carrying value. No transfers between levels have occurred during the periods presented.
	Assets and liabilities measured at fair value on a recurring basis as of June 30, 2014 and December 31, 2013 are as follows (in thousands):
					Fair Value Measurements Using
		Balance as of			Quoted Prices		Significant		Significant
		June 30,			in Active		Other		Unobservable
		2014			Markets for		Observable		Inputs
					Identical Assets		Inputs		(Level 3)
					(Level 1)		(Level 2)
	Assets:
	Money market funds(1)	$	8,683		$	8,683	$	-	$	-
	Commercial paper		30,497					30,497
	Corporate debt securities		62,565					62,565
	Government sponsored entities		4,002			-		4,002
	Total	$	105,747		$	8,683	$	97,064	$	-
	-1	Included within cash and cash equivalents and marketable securities on the Company’s condensed balance sheet.
					Fair Value Measurements Using
		Balance as of			Quoted Prices		Significant		Significant
		December 31,			in Active		Other		Unobservable
		2013			Markets for		Observable		Inputs
					Identical Assets		Inputs		(Level 3)
					(Level 1)		(Level 2)
	Liabilities:
	Series C preferred stock warrants	$	1,165			-		-	$	1,165
	Series D preferred stock warrants		2,330			-		-		2,330
	Series E preferred stock warrants		480			-		-		480
	Total	$	3,975			-		-	$	3,975
	The Company’s investments in money market funds are valued based on publicly available quoted market prices for identical securities as of June 30, 2014. The Company determines the fair value of corporate bonds and other government-sponsored enterprise related securities with the aid of valuations provided by third parties using proprietary valuation models and analytical tools. These valuation models and analytical tools use market pricing or prices for similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers. The Company validates the valuations received from its primary pricing vendors for its level 2 securities by examining the inputs used in that vendor’s pricing process and determines whether they are reasonable and observable. The Company also compares those valuations to recent reported trades for those securities. The Company did not adjust any of the valuations received from these independent third parties with respect to any of its level 2 securities at June 30, 2014.
	As discussed in Note 2 above, all of the outstanding warrants to purchase shares of preferred stock automatically converted into warrants to purchase shares of common stock in connection with the IPO and are accounted for as equity from the conversion date forward. Prior to the conversion, the Company estimated the fair value of convertible preferred stock warrants at the time of issuance and subsequent remeasurement using the Black-Scholes option-pricing model at each reporting date, using the following inputs: the risk-free interest rates; the expected dividend rates; the remaining expected life of the warrants; and the expected volatility of the price of the underlying common stock.
	The following assumptions were used in the Black-Scholes option-pricing model to determine the fair value of the convertible preferred stock warrant liability as of February 10, 2014, the conversion date, and December 31, 2013:
		February 10,			December 31,
		2014			2013
	Assumptions:
	Risk-free interest rate	0.07%-2.64%			0.07%-3.04%
	Expected dividend yield		0%			0%
	Expected volatility	69.66%-87.51%			66.49%-85.10%
	Expected term (in years)	0.29-9.89			0.39-9.99
	The following table provides a reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs (in thousands):
		Warrant
		Liability
	Balance at January 1, 2013	$	1,556
	Issuance of warrants		606
	Exercise of tranche rights		(118	)
	Change in fair value(1)		1,931
	Balance at December 31, 2013		3,975
	Change in fair value(1)		3,634
	Reclassification of warrants(2)		(7,609	)
	Balance at June 30, 2014	$	-
	-1	The changes in the fair value of the convertible preferred stock warrants were recorded as increase or reduction to other income (expenses) in the statement of operations.
	-2	In connection with the completion of the Company’s IPO in February 2014, the Company reclassified the warranty liability to stockholders’ equity as the warrants met the definition of an equity instrument under derivative accounting guidance.

Investments_in_Marketable_Secu

Investments in Marketable Securities	6 Months Ended
	Jun. 30, 2014
Investments in Marketable Securities	'
	4. Investments in Marketable Securities
	Investments classified as available-for-sale at June 30, 2014 consisted of the following (in thousands):
		Maturity (in years)	Amortized		Gross		Gross			Aggregate
			Cost		Unrealized		Unrealized			Estimated
					Gains		Losses			Fair Value
	Marketable Securities:
	Commercial paper	1 year or less	$	30,477	$	20	$	-		$	30,497
	Corporate debt securities	2 years or less(1)		62,556		12		(3	)		62,565
	Government sponsored entities	1-2 years		4,004		-		(2	)		4,002
	Total available-for-sale securities		$	97,037	$	32	$	(5	)	$	97,064
	-1	At June 30, 2014, $12.9 million of these securities were scheduled to mature outside of one year.
	The Company did not realize any gains or losses on sales or maturities of available-for-sale securities for the three and six months ended June 30, 2014. Unrealized gains and losses on available-for-sale securities are included as a component of comprehensive loss. At June 30, 2014, there were 9 securities in unrealized loss positions. These securities have not been in a continuous unrealized loss position for more than 12 months. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell these investments before recovery of their amortized cost basis which may be at maturity. The Company reviews its investments to identify and evaluate investments that have an indication of possible other-than-temporary impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, the financial condition and near-term prospects of the investee, and the Company’s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.

Other_Balance_Sheet_Items

Other Balance Sheet Items	6 Months Ended
	Jun. 30, 2014
Other Balance Sheet Items	'
	5. Other Balance Sheet Items
	Prepaid and other current assets consisted of the following (in thousands):
		June 30,			December 31,
		2014			2013
	Prepaid insurance	$	420		$	72
	Interest receivable		351			-
	Prepaid other		421			170
		$	1,192		$	242
	Property and equipment consisted of the following (in thousands):
		June 30,			December 31,
		2014			2013
	Computer equipment and software	$	79		$	45
	Construction in progress		61			-
	Leasehold improvements		34			5
	Furniture and fixtures		16			16
	Office equipment		16			12
	Machinery and equipment		4			4
			210			82
	Less accumulated depreciation and amortization		(74	)		(56	)
		$	136		$	26
	Accrued liabilities consisted of the following (in thousands):
		June 30,			December 31,
		2014			2013
	Clinical trial accruals	$	1,714		$	565
	Payroll and related expenses		976			475
	Manufacturing cost accrual		334			772
	Other accrued expenses		928			315
		$	3,952		$	2,127

LongTerm_Debt

Long-Term Debt	6 Months Ended
	Jun. 30, 2014
Long-Term Debt	'
	6. Long-Term Debt
	On December 27, 2013, the Company entered into a term loan facility with Oxford Finance LLC and its assignees. The loan facility provides funding for an aggregate principal amount of $15.0 million which was funded at closing. The term loan is collateralized by the Company’s assets excluding intellectual property and bears interest at a fixed rate of 8.99% per annum with interest only payments for 12 months beginning on February 1, 2014 and equal monthly principal and interest payments over 36 months thereafter. In accordance with the terms of the loan facility, upon the completion of the Company’s IPO in February 2014, the interest only period was extended by an additional 6 months to 18 months with equal monthly principal and interest payments over 30 months thereafter (reduced from 36 months). The loan will mature on January 1, 2018. Upon repayment of the term loan, the Company is required to make a final payment to the lenders equal to 3% of the original principal balance of the loan. The Company incurred loan origination fees of $0.1 million which were recorded as a loan discount and additional issuance costs of $0.1 million which were recorded as a deferred asset accounted for by utilizing the effective interest method. The Company recorded $0.1 million and $0.5 million of interest expense for the three and six months ended June 30, 2014, of which $43,000 and $85,000 related to the amortization of debt discount and deferred asset related to this term loan.
	The Company is permitted to make voluntary prepayments of the term loan with a prepayment fee equal to (i) 3% of the term loan prepaid during the first 12 months, (ii) 2% of the term loan prepaid in months 13-24 and (iii) 1% of the term loan prepaid thereafter. The Company is required to make mandatory prepayments of the outstanding term loan upon the acceleration by the lenders of such term loan following the occurrence of an event of default, along with a payment of the final payment, the prepayment fee and any other obligations that are due and payable at the time of the prepayment. The Company is also subject to certain non-financial covenants.  As of June 30, 2014, the Company has not experienced any events of default and was in compliance with all covenants under the loan facility.
	Future minimum payments under the term loan are as follows (in thousands):
	Year Ending December 31,
	2014 (Six months remaining)	$	675
	2015		3,588
	2016		6,722
	2017		6,722
	2018		1,011
	Total future minimum payments		18,718
	Less amounts representing interest and fees		(3,268	)
	Less end of term payment		(450	)
	Gross balance of long-term debt		15,000
	Less unamortized discount		(495	)
	Total present value of long-term debt	$	14,505

Convertible_Preferred_Stock_Wa

Convertible Preferred Stock Warrants	6 Months Ended
	Jun. 30, 2014
Convertible Preferred Stock Warrants	'
	7. Convertible Preferred Stock Warrants
	Prior to the completion of the Company’s IPO in February 2014, the Company accounted for the warrants it had previously issued for the purchase of the Company’s convertible preferred stock in connection with its 2009, 2010, 2011 and 2012 convertible notes and its January and December 2013 credit facilities, as liabilities based on the “deemed liquidation” terms of the convertible preferred stock. Upon consummation of the Company’s IPO in February 2014, all of the outstanding warrants to purchase shares of preferred stock automatically converted into warrants to purchase shares of common stock at a 1-to-1 ratio, adjusted for the January 16, 2014 reverse stock split, and the Company reclassified the warrant liability to stockholders’ equity as the warrants met the definition of an equity instrument under the derivatives accounting guidance.
	The following table summarizes the shares subject to outstanding warrants and the corresponding exercise price as of June 30, 2014 and December 31, 2013:
		Number of Shares Outstanding
		June 30,		December 31,		Exercise Price		Expiration Date
		2014		2013
	May 2009 Series C Warrants		-		507,910	$	0.862	22-May-14
	October 2009 Series C Warrants		-		464,035	$	0.862	9-Oct-14
	January 2010 Series C Warrants		-		457,285	$	0.862	8-Jan-15
	December 2011 Series D Warrants		-		654,292	$	0.862	15-Dec-16
	April 2012 Series D Warrants		-		654,291	$	0.862	20-Apr-07
	July 2012 Series D Warrants		-		348,027	$	0.862	18-Jul-17
	August 2012 Series D Warrants		-		348,027	$	0.862	28-Aug-17
	January 2013 Series D Warrants		-		174,014	$	0.862	9-Jan-23
	December 2013 Series E Warrants		-		261,020	$	1.724	27-Dec-23
	Common Stock Warrants		708,207		-	$3.879 - $7.758
	Total		708,207		3,868,901
	Series C and D Preferred Stock Warrants
	In connection with convertible notes that were fully converted to preferred stock prior to December 31, 2013, the Company issued warrants to note holders for the purchase of shares of Series C Preferred Stock (“Series C warrants”) and Series D Preferred Stock (“Series D warrants”). At December 31, 2013 there were Series C warrants outstanding for the purchase of an aggregate of 1,429,230 shares of Series C Preferred Stock and Series D warrants outstanding for the purchase of an aggregate of 2,004,637 shares of Series D Preferred Stock. Upon completion of the Company’s IPO in February 2014, these warrants converted into warrants to purchase an aggregate of 763,073 shares of the Company’s common stock at an exercise price of $3.879 per share. In May 2014, warrants subject to an aggregate of 112,867 shares of common stock were exercised, a portion of which were exercised through a cashless net exercise, and resulted in a total issuance of 100,467 shares of common stock.
	January and December 2013 Preferred Stock Warrants
	In connection with a January 2013 credit facility which was paid in full prior to December 31, 2013, the Company issued a warrant for the purchase of 174,014 shares of Series D Preferred Stock at $0.862 per share. The warrant was immediately exercisable and would have expired on January 9, 2023. Upon completion of the Company’s IPO in February 2014, the warrant converted into a warrant for the purchase of 38,669 shares of the Company’s common stock at an exercise price of $3.879 per share. On February 28, 2014, the warrant was fully exercised through a cashless net exercise and the Company issued a net of 33,469 shares of common stock.
	In connection with the funding of the December 2013 term loan, the Company issued warrants to the lenders to purchase an aggregate of 261,020 shares of Series E Preferred Stock at a purchase price of $1.724 per share. The warrants were exercisable on December 27, 2013 and will expire on December 27, 2023. The warrants were valued at $0.5 million at issuance and were recorded as a loan discount, utilizing the Black-Scholes option-pricing model and are being amortized to interest expense over the expected term of the loan agreement. Upon completion of the Company’s IPO in February 2014, the warrants converted into warrants to purchase an aggregate of 58,001 shares of the Company’s common stock at an exercise price of $7.76 per share.

Stockholders_Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity	'
	8. Stockholders’ Equity
	Initial Public Offering and Related Transactions
	On February 10, 2014, the Company completed its IPO selling 8,050,000 shares of common stock at $12.00 per share. Proceeds from the Company’s IPO, net of underwriting discounts and commissions and other offering costs, were $86.7 million.
	In addition, each of the following occurred in connection with the completion of the Company’s IPO on February 10, 2014:
	·	the conversion of all outstanding shares of convertible preferred stock into 14,397,836 shares of the Company’s common stock; and
	·	the conversion of warrants to purchase 3,868,901 shares of convertible preferred stock into warrants to purchase 859,743 shares of the Company’s common stock and the resultant reclassification of the warrant liability to additional paid-in capital.
	On February 10, 2014, the Company amended its Certificate of Incorporation to decrease the number of authorized shares of preferred stock to 10,000,000 with a par value of $0.0001 per share, and to increase the number of authorized shares of common stock to 200,000,000 with a par value of $0.0001 per share.
	Convertible Preferred Stock
	Prior to its conversion in the IPO, the Company’s convertible preferred stock was classified on the Company’s balance sheets as temporary equity instead of stockholders’ (deficit) equity in accordance with authoritative guidance for the classification and measurement of redeemable securities. Upon certain change in control events that are outside of the Company’s control, including liquidation, sale or transfer of control of the Company, holders of the convertible preferred stock could cause its redemption.
	Employee Stock Purchase Plan
	On January 15, 2014, the Company’s board of directors and stockholders approved and adopted the ESPP. The ESPP became effective and the first purchase period began upon the execution and delivery of the underwriting agreement for the IPO on February 4, 2014. The ESPP permits eligible employees to make payroll deductions to purchase up to $25,000 of the Company’s common stock on regularly scheduled purchase dates at a discount. Offering periods under the ESPP are not more than 27 months in duration and shares are purchased at 85% of the lower of the closing price for the Company’s common stock on the first day of the offering period or the date of purchase. The ESPP initially authorized the issuance of 300,000 shares of the Company’s common stock pursuant to rights granted to employees for their payroll deductions. The number of shares of common stock reserved for issuance will automatically increase on January 1st of each calendar year, from January 1, 2015 through January 1, 2024, by an amount equal to the lessor of (a) 1% of the total number of shares of the Company’s common stock outstanding on December 31st of the preceding calendar year, (b) 530,000 shares, or (c) a number determined by the Company’s board of directors that is less than (a) and (b).
	During the three and six months ended June 30, 2014, 7,895 shares of common stock were issued pursuant to ESPP purchases.
	2014 Equity Incentive Plan
	On January 15, 2014, the Company’s board of directors and stockholders approved and adopted the 2014 Plan. Upon adoption of the 2014 Plan, the Company restricted future grants from its 2010 Plan. The 2014 Plan initially reserved 1,110,000 new shares, plus an amount not to exceed 3,059,326 shares which represented (1) the number of shares reserved for issuance under the 2010 Plan at the time the 2014 Plan became effective and (2) any shares subject to outstanding stock options or other stock awards that would have otherwise returned to the 2010 plan (such as upon the expiration or termination of a stock award prior to vesting). The number of shares of common stock reserved for issuance under the 2014 Plan will automatically increase on January 1st of each year, from January 1, 2015 through January 1, 2024, by 4% of the total number of shares of the Company’s common stock outstanding on December 31st of the preceding calendar year, or a lesser number of shares determined by the Company’s board of directors. The maximum number of shares that may be issued upon the exercise of awards under the 2014 Plan is 8,318,652 shares.
	During the three and six months ended June 30, 2014, 1,111 shares of common stock were issued pursuant to stock option exercises.

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies	'
	9. Commitments and Contingencies
	Lease
	In June 2011, the Company entered into a noncancelable operating lease for corporate office space (the “Lease”). In June 2012, the Company amended the Lease for additional square footage (the “First Amendment”), which term was extended through a second amendment (the “Second Amendment”) in November 2012. In February 2014, the Company entered into a third amendment to its Lease (the “Third Amendment”) and a lease assignment (the “Lease Assignment”) to provide for additional space.
	The Company is subject to charges for common area maintenance and other costs pursuant to its lease agreements. As of June 30, 2014, the Lease, as modified by the Second Amendment, was to expire in August 2016, and the Third Amendment was to expire in November 2014. As more fully described in Note 10 below, in July 2014, the Company entered into a fourth amendment to the Lease (the “Fourth Amendment”), which superseded the Second Amendment, the Third Amendment and the Lease Assignment and extended the term of the Lease.
	The Lease, as amended, provides for abatement of rent during certain periods and escalating rent payments throughout the term of the Lease.  Rent expense is being recorded on straight line basis over the life of the Lease. If a lease has provisions that provide for rent abatement during certain periods or escalating rent payments, the difference between the rent expense and rent paid is recorded as deferred rent.
	Patent Assignment Agreement
	In September 2011, the Company entered into a patent assignment agreement with Concert Pharmaceuticals, Inc. (“Concert”) pursuant to which Concert assigned to the Company a U.S. patent application relating to deuterated pirfenidone. Under the terms of the agreement, Concert is eligible to receive certain royalty payments (the “Royalty Payments”), equal to a percentage in the low single digits of net sales in the United States invoiced by the Company, or any of its affiliates, with respect to certain pharmaceutical products containing deuterated pirfenidone. If the Company sells to another party all of its U.S. rights to certain deuterated pirfenidone products, or if the Company grants to another party a license to sell certain deuterated pirfenidone products in the United States, Concert will receive an amount (the “Sublicense/Sale Payments”), equal to a percentage in the teens of any proceeds the Company receives therefrom that are attributable to the rights to such deuterated pirfenidone products in the United States If the Company is acquired in a change in control transaction at any time while the Company, or any of its affiliates, own certain patents or patent applications related to deuterated pirfenidone, Concert will receive 1.44% of any proceeds the Company receives in such transaction. Such payment is to be applied as a credit to any future Royalty Payments and Sublicense/Sale Payments that may be due to Concert under the agreement. The agreement expires upon the earlier to occur of (1) receipt by Concert of the final Sublicense/Sale Payment arising from (a) the sale of the Company’s U.S. rights to certain deuterated pirfenidone products or (b) the Company’s grant of an exclusive license to sell certain deuterated pirfenidone products in the United States in all indications and fields, or (2) the expiration of the last claim owned by the Company or any of its affiliates in certain patents or patent applications related to deuterated pirfenidone.

Subsequent_Events

Subsequent Events	6 Months Ended
	Jun. 30, 2014
Subsequent Events	'
	10. Subsequent Events
	Joint Development Agreement
	In July 2014, the Company entered into a License and Joint Development Agreement with an early development stage company for certain intellectual property rights related to deuterated oral small molecule compounds for the treatment of certain movement disorders that are distinct from and not related to our late stage SD-809 program. These compounds are in the early stage of development and the Company plans to advance the program in collaboration with its partner through an agreed upon phase of development. These compounds could be further advanced or partnered in the future based on strategic considerations and availability of resources.
	Sale of Common Stock
	In July 2014, the Company completed a follow-on offering whereby it issued an aggregate 3,622,500 shares of common stock at $19.25 per share. Proceeds from the follow-on offering, net of underwriting discounts, commissions and estimated offering expenses, were approximately $64.9 million.
	Amendment to Lease
	In July 2014, the Company entered into the Fourth Amendment to the Lease, pursuant to which the Company will lease new office space that will serve as its corporate headquarters, replacing its current facilities. The Lease, as amended by the Fourth Amendment, is scheduled to commence in two phases, with a portion of space anticipated to become available on September 1, 2014 and the remaining portion of space becoming available no earlier than January 1, 2015, subject to certain exceptions.  The Lease, as amended, will expire 66 months after the date on which the space for the initial phase becomes available. The Lease will have an initial monthly rent of approximately $50,600 per month for the first phase, and an additional $18,200 per month as the remaining portion of the space becomes available, subject to annual rent increases.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2014
Basis of Presentation	'
	Basis of Presentation
	The Company’s financial statements are prepared in accordance with U.S. generally accepted accounting principles and with the rules and regulations of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements. These unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, consisting of only normal recurring accruals, which in the opinion of management are necessary to present fairly the Company’s financial position as of the interim date and results of operations for the interim periods presented. The preparation of the Company’s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to the valuation of convertible preferred stock warrants, equity awards and clinical trial accruals. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.
	Interim results are not necessarily indicative of results for a full year or future periods, and these condensed financial statements should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2013, included in its Annual Report on Form 10-K filed with the SEC on March 28, 2014.
Segment Reporting	'
	Segment Reporting
	Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment.
Reverse Stock Split	'
	Reverse Stock Split
	On January 16, 2014, the Company effected a 1-for-4.5 reverse stock split of the Company’s issued and outstanding shares of common stock. All issued and outstanding common stock and per share amounts contained in the Company’s financial statements have been retroactively adjusted to reflect the January 2014 reverse stock split for all periods presented.
Cash, Cash Equivalents and Marketable Securities	'
	Cash, Cash Equivalents and Marketable Securities
	Cash and cash equivalents consist of cash and highly liquid securities with maturities at the date of acquisition of ninety days or less. Investments with maturities at the date of acquisition of more than ninety days are considered marketable securities and have been classified by management as available-for-sale. Such investments are carried at fair value, with unrealized gains and losses included as a separate component of stockholders’ equity. Realized gains and losses from the sale of available-for-sale securities or the amounts, net of tax, reclassified out of accumulated other comprehensive income, if any, are determined on a specific identification basis.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The Company measures certain financial assets and liabilities at fair value based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants.
Convertible Preferred Stock Warrant	'
	Convertible Preferred Stock Warrants
	The Company accounts for its warrants and other derivative financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument. Warrants classified as derivative liabilities are recorded on the Company’s balance sheet at their fair value on the date of issuance and are revalued at each subsequent balance sheet date, with fair value changes recognized as increases or reductions to other income (expense) in the statements of operations. The Company’s convertible preferred stock warrants were classified as liabilities, and the Company estimated the fair value of these liabilities using option pricing models and assumptions that were based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for expected volatility, expected life, yield, and risk-free interest rate. In connection with the completion of the Company’s initial public offering (“IPO”) in February 2014, all the outstanding warrants to purchase shares of preferred stock automatically converted into warrants to purchase shares of common stock. As a result of the IPO and warrant conversion, the Company reclassified the warrant liability as stockholders’ equity because the converted warrants met the definition of an equity instrument under derivative accounting guidance.  The Company performed the final remeasurement of the warrant liability as of the IPO date in February 2014, and recorded the $3.6 million change in fair value as other income (expense) at that time.
Stock-Based Compensation Expense	'
	Stock-Based Compensation Expense
	Stock options issued pursuant to the Company’s 2014 Equity Incentive Plan (the “2014 Plan”) and 2010 Equity Incentive Plan (the “2010 Plan”) and shares subject to purchase through the Company’s 2014 Employee Stock Purchase Plan (the “ESPP”) are valued using the Black-Scholes option pricing model on the date of grant or subscription period. This option pricing model involves a number of estimates, including the expected term of an award or subscription period, the anticipated stock volatility and risk-free interest rates. Stock-based compensation expense is recognized using the straight-line method and is based on the value of the portion of stock awards that are ultimately expected to vest or the number of shares estimated to be issued pursuant to ESPP.
	The table below summarizes the total stock-based compensation expense included in the Company’s statements of operations for stock options and shares subject to purchase under the ESPP for the periods presented (in thousands):
		Three Months Ended June 30,				Six Months Ended June 30,
		2014		2013		2014		2013
	Research and development	$	466	$	20	$	595	$	37
	General and administrative		441		1		816		41
	Total stock-based compensation expense	$	907	$	21	$	1,411	$	78
Net Loss Per Share	'
	Net Loss per Share
	Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, convertible preferred stock, unvested restricted common stock subject to repurchase, stock options and convertible preferred stock warrants are considered to be potentially dilutive securities but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. Therefore, basic and diluted net loss per share were the same for all periods presented.
	The following table sets forth the total number of outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive:
		June 30,
		2014		2013
	Convertible preferred stock		-		9,625,465
	Warrants to purchase convertible preferred stock		-		863,613
	Warrants to purchase common stock		708,207		-
	Common stock options		2,009,646		552,116
	Common stock subject to repurchase		799,068		-
			3,516,921		11,041,194
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminates the financial reporting distinction between development stage entities and other reporting entities, thereby eliminating the requirements to present inception-to-date information in the statements of operations and stockholders’ equity and cash flow, or label the financial statements as those of a development stage entity. The Company has elected to early adopt this guidance, as permitted, for its financial statements for the year ended December 31, 2014, including this quarterly report, and therefore has no longer labeled its financial statements as those of a development stage entity or included any inception-to-date information.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2014
Summary of Total Stock-Based Compensation Expense Included in Statements of Operations for Stock Options and ESPP	'
	The table below summarizes the total stock-based compensation expense included in the Company’s statements of operations for stock options and shares subject to purchase under the ESPP for the periods presented (in thousands):
		Three Months Ended June 30,				Six Months Ended June 30,
		2014		2013		2014		2013
	Research and development	$	466	$	20	$	595	$	37
	General and administrative		441		1		816		41
	Total stock-based compensation expense	$	907	$	21	$	1,411	$	78
Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss Per Share	'
	The following table sets forth the total number of outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive:
		June 30,
		2014		2013
	Convertible preferred stock		-		9,625,465
	Warrants to purchase convertible preferred stock		-		863,613
	Warrants to purchase common stock		708,207		-
	Common stock options		2,009,646		552,116
	Common stock subject to repurchase		799,068		-
			3,516,921		11,041,194

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2014
Assets and Liabilities Measured at Fair Value on Recurring Basis	'
	Assets and liabilities measured at fair value on a recurring basis as of June 30, 2014 and December 31, 2013 are as follows (in thousands):
					Fair Value Measurements Using
		Balance as of			Quoted Prices		Significant		Significant
		June 30,			in Active		Other		Unobservable
		2014			Markets for		Observable		Inputs
					Identical Assets		Inputs		(Level 3)
					(Level 1)		(Level 2)
	Assets:
	Money market funds(1)	$	8,683		$	8,683	$	-	$	-
	Commercial paper		30,497					30,497
	Corporate debt securities		62,565					62,565
	Government sponsored entities		4,002			-		4,002
	Total	$	105,747		$	8,683	$	97,064	$	-
	-1	Included within cash and cash equivalents and marketable securities on the Company’s condensed balance sheet.
					Fair Value Measurements Using
		Balance as of			Quoted Prices		Significant		Significant
		December 31,			in Active		Other		Unobservable
		2013			Markets for		Observable		Inputs
					Identical Assets		Inputs		(Level 3)
					(Level 1)		(Level 2)
	Liabilities:
	Series C preferred stock warrants	$	1,165			-		-	$	1,165
	Series D preferred stock warrants		2,330			-		-		2,330
	Series E preferred stock warrants		480			-		-		480
	Total	$	3,975			-		-	$	3,975
Assumptions used to Determine Fair Value of Convertible Preferred Stock Warrant Liability	'
	The following assumptions were used in the Black-Scholes option-pricing model to determine the fair value of the convertible preferred stock warrant liability as of February 10, 2014, the conversion date, and December 31, 2013:
		February 10,			December 31,
		2014			2013
	Assumptions:
	Risk-free interest rate	0.07%-2.64%			0.07%-3.04%
	Expected dividend yield		0%			0%
	Expected volatility	69.66%-87.51%			66.49%-85.10%
	Expected term (in years)	0.29-9.89			0.39-9.99
Reconciliation of all Liabilities Measured at Fair Value Using Level Three Significant Unobservable Inputs	'
	The following table provides a reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs (in thousands):
		Warrant
		Liability
	Balance at January 1, 2013	$	1,556
	Issuance of warrants		606
	Exercise of tranche rights		(118	)
	Change in fair value(1)		1,931
	Balance at December 31, 2013		3,975
	Change in fair value(1)		3,634
	Reclassification of warrants(2)		(7,609	)
	Balance at June 30, 2014	$	-
	-1	The changes in the fair value of the convertible preferred stock warrants were recorded as increase or reduction to other income (expenses) in the statement of operations.
	-2	In connection with the completion of the Company’s IPO in February 2014, the Company reclassified the warranty liability to stockholders’ equity as the warrants met the definition of an equity instrument under derivative accounting guidance.

Investments_in_Marketable_Secu1

Investments in Marketable Securities (Tables)	6 Months Ended
	Jun. 30, 2014
Summary of Investments Classified as Available-For-Sale Securities	'
	Investments classified as available-for-sale at June 30, 2014 consisted of the following (in thousands):
		Maturity (in years)	Amortized		Gross		Gross			Aggregate
			Cost		Unrealized		Unrealized			Estimated
					Gains		Losses			Fair Value
	Marketable Securities:
	Commercial paper	1 year or less	$	30,477	$	20	$	-		$	30,497
	Corporate debt securities	2 years or less(1)		62,556		12		(3	)		62,565
	Government sponsored entities	1-2 years		4,004		-		(2	)		4,002
	Total available-for-sale securities		$	97,037	$	32	$	(5	)	$	97,064

Other_Balance_Sheet_Items_Tabl

Other Balance Sheet Items (Tables)	6 Months Ended
	Jun. 30, 2014
Summary of Prepaid and Other Current Assets	'
	Prepaid and other current assets consisted of the following (in thousands):
		June 30,			December 31,
		2014			2013
	Prepaid insurance	$	420		$	72
	Interest receivable		351			-
	Prepaid other		421			170
		$	1,192		$	242
Summary of Property and Equipment Balances	'
	Property and equipment consisted of the following (in thousands):
		June 30,			December 31,
		2014			2013
	Computer equipment and software	$	79		$	45
	Construction in progress		61			-
	Leasehold improvements		34			5
	Furniture and fixtures		16			16
	Office equipment		16			12
	Machinery and equipment		4			4
			210			82
	Less accumulated depreciation and amortization		(74	)		(56	)
		$	136		$	26
Summary of Accrued Liabilities	'
	Accrued liabilities consisted of the following (in thousands):
		June 30,			December 31,
		2014			2013
	Clinical trial accruals	$	1,714		$	565
	Payroll and related expenses		976			475
	Manufacturing cost accrual		334			772
	Other accrued expenses		928			315
		$	3,952		$	2,127

LongTerm_Debt_Tables

Long-Term Debt (Tables)	6 Months Ended
	Jun. 30, 2014
Future Minimum Payments under Term Loan	'
	Future minimum payments under the term loan are as follows (in thousands):
	Year Ending December 31,
	2014 (Six months remaining)	$	675
	2015		3,588
	2016		6,722
	2017		6,722
	2018		1,011
	Total future minimum payments		18,718
	Less amounts representing interest and fees		(3,268	)
	Less end of term payment		(450	)
	Gross balance of long-term debt		15,000
	Less unamortized discount		(495	)
	Total present value of long-term debt	$	14,505

Convertible_Preferred_Stock_Wa1

Convertible Preferred Stock Warrants (Tables)	6 Months Ended
	Jun. 30, 2014
Summary of Outstanding Convertible Preferred Stock Warrants and Corresponding Exercise Price	'
	The following table summarizes the shares subject to outstanding warrants and the corresponding exercise price as of June 30, 2014 and December 31, 2013:
		Number of Shares Outstanding
		June 30,		December 31,		Exercise Price		Expiration Date
		2014		2013
	May 2009 Series C Warrants		-		507,910	$	0.862	22-May-14
	October 2009 Series C Warrants		-		464,035	$	0.862	9-Oct-14
	January 2010 Series C Warrants		-		457,285	$	0.862	8-Jan-15
	December 2011 Series D Warrants		-		654,292	$	0.862	15-Dec-16
	April 2012 Series D Warrants		-		654,291	$	0.862	20-Apr-07
	July 2012 Series D Warrants		-		348,027	$	0.862	18-Jul-17
	August 2012 Series D Warrants		-		348,027	$	0.862	28-Aug-17
	January 2013 Series D Warrants		-		174,014	$	0.862	9-Jan-23
	December 2013 Series E Warrants		-		261,020	$	1.724	27-Dec-23
	Common Stock Warrants		708,207		-	$3.879 - $7.758
	Total		708,207		3,868,901

Organization_Additional_Inform

Organization - Additional Information (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Organization [Line Items]	'	'
Accumulated deficit	($85,988)	($65,480)

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Details) (USD $)	0 Months Ended	6 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Jan. 16, 2014	Jun. 30, 2014	Dec. 31, 2013
		Segment
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Number of operating segment	'	1	'
Reverse stock split, conversion ratio	0.22	'	'
Change in fair value of preferred stock warrant liability	'	$3,634	$1,931

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Summary of Total Stock-Based Compensation Expense Included in Statements of Operations for Stock Options and ESPP (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'	'
Stock-based compensation	$907	$21	$1,411	$78
Research and Development Expense	'	'	'	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'	'
Stock-based compensation	466	20	595	37
General and Administrative Expense	'	'	'	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'	'
Stock-based compensation	$441	$1	$816	$41

Summary_of_Significant_Account5

Summary of Significant Accounting Policies - Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss Per Share (Details)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Summary Of Significant Accounting Policies [Line Items]	'	'
Potentially dilutive securities excluded in calculation of diluted net loss per share	3,516,921	11,041,194
Convertible preferred stock	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'
Potentially dilutive securities excluded in calculation of diluted net loss per share	'	9,625,465
Warrants to purchase convertible preferred stock	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'
Potentially dilutive securities excluded in calculation of diluted net loss per share	'	863,613
Warrants to purchase common stock	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'
Potentially dilutive securities excluded in calculation of diluted net loss per share	708,207	'
Common stock options	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'
Potentially dilutive securities excluded in calculation of diluted net loss per share	2,009,646	552,116
Common stock subject to repurchase	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'
Potentially dilutive securities excluded in calculation of diluted net loss per share	799,068	'

Fair_Value_Measurements_Assets

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) (Fair Value, Measurements, Recurring, USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Assets	$105,747	'
Liabilities	'	3,975
Series C Preferred Stock Warrants	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Liabilities	'	1,165
Series D Preferred Stock Warrants	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Liabilities	'	2,330
Series E Preferred Stock Warrants	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Liabilities	'	480
Corporate Debt Securities	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Assets	62,565	'
US Government-sponsored Enterprises Debt Securities	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Assets	4,002	'
Money Market Funds	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Assets	8,683	'
Commercial Paper	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Assets	30,497	'
Quoted Prices in Active Markets for Identical Assets (Level 1)	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Assets	8,683	'
Quoted Prices in Active Markets for Identical Assets (Level 1) | Money Market Funds	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Assets	8,683	'
Significant Other Observable Inputs (Level 2)	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Assets	97,064	'
Significant Other Observable Inputs (Level 2) | Corporate Debt Securities	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Assets	62,565	'
Significant Other Observable Inputs (Level 2) | US Government-sponsored Enterprises Debt Securities	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Assets	4,002	'
Significant Other Observable Inputs (Level 2) | Commercial Paper	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Assets	30,497	'
Significant Unobservable Inputs (Level 3)	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Liabilities	'	3,975
Significant Unobservable Inputs (Level 3) | Series C Preferred Stock Warrants	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Liabilities	'	1,165
Significant Unobservable Inputs (Level 3) | Series D Preferred Stock Warrants	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Liabilities	'	2,330
Significant Unobservable Inputs (Level 3) | Series E Preferred Stock Warrants	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Liabilities	'	$480

Fair_Value_Measurements_Assump

Fair Value Measurements - Assumptions used to Determine Fair Value of Convertible Preferred Stock Warrant Liability (Details)	0 Months Ended	12 Months Ended
	Feb. 10, 2014	Dec. 31, 2013
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]	'	'
Expected dividend yield	0.00%	0.00%
Minimum	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]	'	'
Risk-free interest rate	0.07%	0.07%
Expected volatility	69.66%	66.49%
Expected term (in years)	'3 months 15 days	'4 months 21 days
Maximum	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]	'	'
Risk-free interest rate	2.64%	3.04%
Expected volatility	87.51%	85.10%
Expected term (in years)	'9 years 10 months 21 days	'9 years 11 months 27 days

Fair_Value_Measurements_Reconc

Fair Value Measurements - Reconciliation of all Liabilities Measured at Fair Value Using Level Three Significant Unobservable Inputs (Details) (USD $)	6 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]	'	'
Beginning Balance	$3,975	$1,556
Issuance of warrants	'	606
Exercise of tranche rights	'	-118
Change in fair value of preferred stock warrant liability	3,634	1,931
Reclassification of warrants	-7,609	'
Ending Balance	'	$3,975

Investments_in_Marketable_Secu2

Investments in Marketable Securities - Summary of Investments Classified as Available-for-Sale Securities (Details) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014
Schedule Of Available For Sale Securities [Line Items]	'
Amortized Cost	97,037
Gross Unrealized Gains	32
Gross Unrealized Losses	-5
Aggregate Estimated Fair Value	97,064
Short-term investments | Commercial Paper	'
Schedule Of Available For Sale Securities [Line Items]	'
Amortized Cost	30,477
Gross Unrealized Gains	20
Aggregate Estimated Fair Value	30,497
Short-term investments | Commercial Paper | Maximum	'
Schedule Of Available For Sale Securities [Line Items]	'
Available for Sale Securities Debt Maturities Period	'1 year
Long-term Investments | Corporate Debt Securities	'
Schedule Of Available For Sale Securities [Line Items]	'
Amortized Cost	62,556
Gross Unrealized Gains	12
Gross Unrealized Losses	-3
Aggregate Estimated Fair Value	62,565
Long-term Investments | Corporate Debt Securities | Maximum	'
Schedule Of Available For Sale Securities [Line Items]	'
Available for Sale Securities Debt Maturities Period	'2 years
Long-term Investments | US Government-sponsored Enterprises Debt Securities	'
Schedule Of Available For Sale Securities [Line Items]	'
Amortized Cost	4,004
Gross Unrealized Losses	-2
Aggregate Estimated Fair Value	4,002
Long-term Investments | US Government-sponsored Enterprises Debt Securities | Minimum	'
Schedule Of Available For Sale Securities [Line Items]	'
Available for Sale Securities Debt Maturities Period	'1 year
Long-term Investments | US Government-sponsored Enterprises Debt Securities | Maximum	'
Schedule Of Available For Sale Securities [Line Items]	'
Available for Sale Securities Debt Maturities Period	'2 years

Investments_in_Marketable_Secu3

Investments in Marketable Securities - Summary of Investments Classified as Available-for-Sale Securities (Parenthetical) (Details) (USD $)	Jun. 30, 2014
In Millions, unless otherwise specified
Schedule Of Available For Sale Securities [Line Items]	'
Available For Sale Securities Scheduled to Mature Outside of one year Fair Value	$12.90

Investments_in_Marketable_Secu4

Investments in Marketable Securities - Summary of Investments Classified as Available-For-Sale Securities (Additional Information) (Details) (USD $)	3 Months Ended	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2014
	Security	Security
Schedule Of Available For Sale Securities [Line Items]	'	'
Number of security in an unrealized loss position for less than 12 months	9	9
Gains or losses on sales or maturities of available-for-sale securities	$0	$0

Other_Balance_Sheet_Items_Summ

Other Balance Sheet Items - Summary of Prepaid and Other Current Assets (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Prepaid And Other Current Assets [Line Items]	'	'
Prepaid insurance	$420	$72
Interest receivable	351	'
Prepaid other	421	170
Prepaid expenses and other current assets	$1,192	$242

Other_Balance_Sheet_Items_Summ1

Other Balance Sheet Items - Summary of Property and Equipment Balances (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property Plant And Equipment [Line Items]	'	'
Property and equipment, gross	$210	$82
Less accumulated depreciation and amortization	-74	-56
Property and equipment, net	136	26
Computer Equipment and Software	'	'
Property Plant And Equipment [Line Items]	'	'
Property and equipment, gross	79	45
Construction in progress	'	'
Property Plant And Equipment [Line Items]	'	'
Property and equipment, gross	61	'
Leasehold Improvements	'	'
Property Plant And Equipment [Line Items]	'	'
Property and equipment, gross	34	5
Furniture and Fixtures	'	'
Property Plant And Equipment [Line Items]	'	'
Property and equipment, gross	16	16
Office Equipment	'	'
Property Plant And Equipment [Line Items]	'	'
Property and equipment, gross	16	12
Machinery and Equipment	'	'
Property Plant And Equipment [Line Items]	'	'
Property and equipment, gross	$4	$4

Other_Balance_Sheet_Items_Summ2

Other Balance Sheet Items - Summary of Accrued Liabilities (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued Liabilities [Line Items]	'	'
Clinical trial accruals	$1,714	$565
Payroll and related expenses	976	475
Manufacturing cost accrual	334	772
Other accrued expenses	928	315
Total accrued liabilities	$3,952	$2,127

LongTerm_Debt_Additional_Infor

Long-Term Debt - Additional Information (Details) (USD $)	0 Months Ended	3 Months Ended	6 Months Ended
	Dec. 27, 2013	Jun. 30, 2014	Jun. 30, 2014
Debt Instrument [Line Items]	'	'	'
Debt instrument maximum borrowing capacity	$15,000,000	'	'
Credit facility fixed interest rate	8.99%	'	'
Debt instrument, interest payment period	'12 months	'	'6 months
Debt instrument, principal and interest payment period	'36 months	'	'
Debt instrument maturity date	1-Jan-18	'	'
Percentage of original principal balance of loan to be paid to lenders	3.00%	'	'
Loan origination fee	100,000	'	'
Debt issuance costs	100,000	'	'
Interest Expense, Debt	'	100,000	500,000
Amortization of debt discount	'	$43,000	$85,000
Debt maturities prepayment terms	'	'	'The Company is permitted to make voluntary prepayments of the term loan with a prepayment fee equal to (i) 3% of the term loan prepaid during the first 12 months, (ii) 2% of the term loan prepaid in months 13-24 and (iii) 1% of the term loan prepaid thereafter.
Revised Period	'	'	'
Debt Instrument [Line Items]	'	'	'
Debt instrument, principal and interest payment period	'	'	'30 months
Debt Instrument Interest payment extended period	'	'	'18 months

LongTerm_Debt_Future_Minimum_P

Long-Term Debt - Future Minimum Payments under Term Loan (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Debt Instrument [Line Items]	'	'
2014 (Six months remaining)	$675	'
2015	3,588	'
2016	6,722	'
2017	6,722	'
2018	1,011	'
Total future minimum payments	18,718	'
Less amounts representing interest and fees	-3,268	'
Less end of term payment	-450	'
Gross balance of long-term debt	15,000	'
Less unamortized discount	-495	-580
Total present value of long-term debt	$14,505	$14,420

Convertible_Preferred_Stock_Wa2

Convertible Preferred Stock Warrants - Additional Information (Details) (USD $)

0 Months Ended

1 Months Ended

6 Months Ended

6 Months Ended

0 Months Ended

In Millions, except Share data, unless otherwise specified

31-May-14

Jan. 16, 2014

Jun. 30, 2014

Feb. 28, 2014

Dec. 31, 2013

Feb. 28, 2014

Feb. 28, 2014

Jun. 30, 2014

Jan. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jan. 16, 2014

Jun. 30, 2014

Initial Public Offering

Jan-13

Jan-13

Jan-13

Series C Preferred Stock

Series D Preferred Stock

Series E Preferred Stock

Series E Preferred Stock

Common Stock Warrant

Common Stock Warrant

Class Of Warrant Or Right [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reverse stock split, conversion ratio

'

0.22

'

'

'

'

'

'

'

'

'

'

'

1

'

Aggregate shares pursuant to warrants issued

'

'

708,207

763,073

3,868,901

'

'

'

'

1,429,230

2,004,637

'

'

'

708,207

Per share exercise price of warrants issued

'

'

'

3.879

'

7.76

3.879

'

'

'

'

'

'

'

'

Warrants exercised into common shares

112,867

'

'

'

'

58,001

38,669

'

'

'

'

'

'

'

'

Common stock issued, net

100,467

'

'

'

'

'

33,469

'

'

'

'

'

'

'

'

Issuance of warrants in purchase of Preferred Stock

'

'

'

'

'

'

'

'

174,014

'

'

'

261,020

'

'

Issuance price of Preferred stock

'

'

'

'

'

'

'

'

$0.86

'

'

'

$1.72

'

'

Warrant expiration date

'

'

'

'

'

'

'

9-Jan-23

'

'

'

27-Dec-23

'

'

'

Estimated fair value of Warrants at issuance date

'

'

'

'

'

'

'

'

'

'

'

$0.50

'

'

'

Convertible_Preferred_Stock_Wa3

Convertible Preferred Stock Warrants - Summary of Outstanding Convertible Preferred Stock Warrants and Corresponding Excercise Price (Details)

Jun. 30, 2014

Feb. 28, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Feb. 28, 2014

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Common Stock Warrant

Common Stock Warrant

Common Stock Warrant

May-09

May-09

Oct-09

Oct-09

Jan-10

Jan-10

Dec-11

Dec-11

Apr-12

Apr-12

Jul-12

Jul-12

Aug-12

Aug-12

Jan-13

Jan-13

Jan-13

Jan-13

Dec-13

Dec-13

Minimum

Maximum

Series C Warrants

Series C Warrants

Series C Warrants

Series C Warrants

Series C Warrants

Series C Warrants

Series D Warrants

Series D Warrants

Series D Warrants

Series D Warrants

Series D Warrants

Series D Warrants

Series D Warrants

Series D Warrants

Series D Warrants

Series D Warrants

Series E Warrants

Series E Warrants

Class Of Warrant Or Right [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of Shares Outstanding

708,207

763,073

3,868,901

708,207

'

'

'

507,910

'

464,035

'

457,285

'

654,292

'

654,291

'

348,027

'

348,027

'

'

'

174,014

'

261,020

Per share exercise price of warrants issued

'

3.879

'

'

3.879

7.758

'

0.862

'

0.862

'

0.862

'

0.862

'

0.862

'

0.862

'

0.862

'

3.879

'

0.862

'

1.724

Expiration date of warrants

'

'

'

'

'

'

22-May-14

'

9-Oct-14

'

8-Jan-15

'

15-Dec-16

'

20-Apr-07

'

18-Jul-17

'

28-Aug-17

'

9-Jan-23

'

9-Jan-23

'

27-Dec-23

'

Stockholders_Equity_Initial_Pu

Stockholders' Equity - Initial Public Offering and Related Transactions - Additional Information (Details) (USD $)	0 Months Ended	3 Months Ended	6 Months Ended
	Feb. 10, 2014	Jun. 30, 2014	Jun. 30, 2014	Feb. 28, 2014	Dec. 31, 2013
Stockholders Equity Note [Line Items]	'	'	'	'	'
Initial public common stock offering, shares	8,050,000	'	'	'	'
Common stock offering price, per share	$12	'	'	'	'
Proceeds from initial public offering, net of underwriting discount and commissions	$86,700,000	'	$86,604,000	'	'
Conversion of outstanding convertible preferred stock	14,397,836	'	'	'	'
Number of Shares Outstanding	'	708,207	708,207	763,073	3,868,901
Preferred stock, shares authorized	10,000,000	'	'	'	'
Preferred stock, par value	$0.00	$0.00	$0.00	'	$0.00
Common stock, shares authorized	200,000,000	200,000,000	200,000,000	'	86,500,000
Common stock, par value	$0.00	$0.00	$0.00	'	$0.00
Stock option exercise	'	1,111	1,111	'	'
Two Thousand Fourteen Equity Incentive Plan	'	'	'	'	'
Stockholders Equity Note [Line Items]	'	'	'	'	'
Shares authorized for issuance	'	1,110,000	1,110,000	'	'
Conditions for issuance of stock reserved	'	'	'The number of shares of common stock reserved for issuance under the 2014 Plan will automatically increase on January 1st of each year, from January 1, 2015 through January 1, 2024, by 4% of the total number of shares of the Company’s common stock outstanding on December 31st of the preceding calendar year, or a lesser number of shares determined by the Company’s board of directors.	'	'
Shares reserved for future issuance	'	8,318,652	8,318,652	'	'
Two Thousand Ten Equity Incentive Plan	'	'	'	'	'
Stockholders Equity Note [Line Items]	'	'	'	'	'
Shares authorized for issuance	'	3,059,326	3,059,326	'	'
Scenario One | Two Thousand Fourteen Equity Incentive Plan	'	'	'	'	'
Stockholders Equity Note [Line Items]	'	'	'	'	'
Annual icreament in number of common stock shares reserved for issuuance as a percentage of common stock shares outstanding	'	'	4.00%	'	'
Employee Stock Purchase Plan	'	'	'	'	'
Stockholders Equity Note [Line Items]	'	'	'	'	'
Maximum amount eligible for employees to purchase share	'	'	$25,000	'	'
Offering price at discount rate for ESPP	'	'	85.00%	'	'
Shares authorized for issuance	'	300,000	300,000	'	'
Conditions for issuance of stock reserved	'	'	'The number of shares of common stock reserved for issuance will automatically increase on January 1st of each calendar year, from January 1, 2015 through January 1, 2024, by an amount equal to the lessor of (a) 1% of the total number of shares of the Company’s common stock outstanding on December 31st of the preceding calendar year, (b) 530,000 shares, or (c) a number determined by the Company’s board of directors that is less than (a) and (b).	'	'
Stock Issued During Period, Shares, Employee Stock Purchase Plans	'	7,895	7,895	'	'
Employee Stock Purchase Plan | Scenario Two	'	'	'	'	'
Stockholders Equity Note [Line Items]	'	'	'	'	'
Annual icreament in number of common stock shares reserved for issuuance	'	'	530,000	'	'
Employee Stock Purchase Plan | Scenario One	'	'	'	'	'
Stockholders Equity Note [Line Items]	'	'	'	'	'
Annual icreament in number of common stock shares reserved for issuuance as a percentage of common stock shares outstanding	'	'	1.00%	'	'
Convertible preferred stock	'	'	'	'	'
Stockholders Equity Note [Line Items]	'	'	'	'	'
Number of Shares Outstanding	3,868,901	'	'	'	'
Common Stock	'	'	'	'	'
Stockholders Equity Note [Line Items]	'	'	'	'	'
Number of Shares Outstanding	859,743	'	'	'	'

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Details)	6 Months Ended
	Jun. 30, 2014
Commitments And Contingencies [Line Items]	'
Noncancelable operating lease for corporate office space	'2011-06
Lease expiration period	'2016-08
Non-cancelable operating lease additional extension period	'3 years
Additional space lease expiration date	30-Nov-14
Lease agreement amended date for extension period	'2014-07
Percentage of Royalty Payments	1.44%
Amendment One	'
Commitments And Contingencies [Line Items]	'
Lease expiration period	'2011-06
Amendment Two	'
Commitments And Contingencies [Line Items]	'
Lease expiration period	'2012-11
Amendment Three	'
Commitments And Contingencies [Line Items]	'
Lease expiration period	'2014-02

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Details) (USD $)	0 Months Ended	6 Months Ended	1 Months Ended	0 Months Ended
	Feb. 10, 2014	Jun. 30, 2014	Jul. 31, 2014	Jul. 11, 2014
			Subsequent Event	Subsequent Event
				Secondary Offering
Subsequent Event [Line Items]	'	'	'	'
Initial public common stock offering, shares	8,050,000	'	'	3,622,500
Common stock offering price, per share	$12	'	'	$19.25
Proceeds from the issuance of common stock, net of fees	$86,700,000	$86,604,000	'	$64,900,000
Description of Lease	'	'The Lease, as amended by the Fourth Amendment, is scheduled to commence in two phases, with a portion of space anticipated to become available on September 1, 2014 and the remaining portion of space becoming available no earlier than January 1, 2015, subject to certain exceptions. The Lease, as amended, will expire 66 months after the date on which the space for the initial phase becomes available.	'	'
Lease expiration term	'	'	'66 months	'
Initial monthly rent for the first phase	'	'	50,600	'
Additional monthly rent after the first phase	'	'	$18,200	'